Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04306081
Other study ID # 20167764
Secondary ID HS-16-00965
Status Recruiting
Phase Phase 4
First received
Last updated
Start date December 14, 2017
Est. completion date March 30, 2021

Study information

Verified date March 2020
Source University of Southern California
Contact Jorge Caro, MPH
Phone 323-382-7646
Email Jorge.Caro@med.usc.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Peripheral arterial disease (PAD) is a manifestation of systemic atherosclerotic cardiovascular disease (ASCVD) and is associated with increase cardiovascular risk. PAD impairs quality of life due to symptoms of claudication, pain at rest or risk of limb loss.

All major societies recognize the importance of LDL reduction in patients with PAD.

Statin therapy improves cardiovascular end-points in patients with PAD and have been shown to improve symptoms of lower extremity intermittent claudication (pain free walking time), 6-minute walking time, ankle-brachial index (ABI), and endothelial function, while decreasing markers of atherosclerosis.

This study aims to demonstrate that in patients with PAD on stable maximal tolerated lipid lowering regimen with a statin, further reduction of LDL with the pro protein converts subtilisin/kexin type 9 (PCSK-9) inhibitor Evolocumab, improves functional status (pain free walking time in particular, but also maximal walking time), lower extremity arterial perfusion and endothelial function (brachial endothelial reactivity).


Description:

This is a double-blinded, prospective, randomized, study in eighty-six subjects with clinical ASCVD with PAD on background treatment with maximal tolerated dose of a statin. Subjects will be assessed based on their medical history and physical examination. Eligible subjects must meet all inclusion criteria and none of the exclusion criteria (listed below). There will be a treatment group and a placebo group, each with equal number of participants (n=43 patients in each group). After consent and enrollment, subjects will have a venous blood sample drawn to perform serum circulating biomarkers of oxidative stress as oxidized low density lipoprotein (oxLDL), oxidized glutathione : reduced glutathione (GSH:GSSG) and soluble CD36 (sCD36). We will then perform: functional walking measurements, pain free walking time (PFWT), and (maximal walking time (MWT), lower extremity arterial perfusion assessment (rest ABI/TBI, post-exercise ABI and bilateral TcPO2), and brachial endothelial function testing (after hyperemia). Subjects will receive monthly subcutaneous injections of Evolocumab 420 mg or placebo injection. The study participants will be seen at three months and six months for follow up and a final assessment at 26 +/-2 weeks, all tests will be repeated for comparison from baseline and/or placebo.


Recruitment information / eligibility

Status Recruiting
Enrollment 86
Est. completion date March 30, 2021
Est. primary completion date December 30, 2020
Accepts healthy volunteers No
Gender All
Age group 40 Years to 85 Years
Eligibility Inclusion Criteria:

- Signed informed consent.

- Age =40 to =85 years of age at the time of consent.

- Diagnosis of ASCVD with peripheral arterial disease, Rutherford class I-VI at the time of diagnosis, confirmed by ABI=0.9 at rest or ABI=0.8 after exercise, angiography, duplex ultrasound or history of lower extremity surgical or endovascular revascularization.

- At least 1 months from last intervention, including surgery or endovascular procedures.

- Stable on maximal tolerated doses of a lipid-lowering regimen for at least 4 weeks.

- Most recent fasting LDL-C =55 mg/dL or non-HDL-C =80 mg/dL.

Exclusion Criteria:

- Subjects with active, non-healed wounds.

- Subjects with anticipated need of cardiac or surgical revascularization procedures.

- Subjects with chronic inflammatory conditions or requiring chronic systemic corticosteroids.

- New York Heart Association (NYHA) class III or IV heart failure, or known left ventricular ejection fraction <30%.

- Uncontrolled arrhythmia.

- Uncontrolled hypertension with systolic BP>180 mmHg or diastolic >100 mmHg.

- Untreated thyroid disease.

- Severe chronic renal disease with estimated glomerular filtration rate (eGFR) <20 mL/min.

- Liver disease with aspartame aminotransferase (AST) or alanine aminotransferase (ALT) =3 times the upper limit of normal.

- Status post-organ transplant.

- Pregnant and breastfeeding women

- Fertile age female not on appropriate birth control.

- Clinically significant disease that, in the opinion of the Principal Investigator, is likely to require surgery or immunotherapy that may interfere with the completion of the study.

- Active cancer or life expectancy of less than two years.

- Chronic anticoagulation or hypercoagulability disorder.

- Atrial fibrillation with a CHADS-VASc Score =2 or any clinical condition which, in the opinion of the Principal Investigator increases the risk of cerebrovascular events.

Study Design


Intervention

Drug:
Evolocumab 140 mg/mL Subcutaneous Injection 1 milliliter (mL) pre-filled injector Pen x 3 for a monthly dose of 420 mg for 6 months.
The study subjects randomized to the treatment study arm will receive monthly subcutaneous injections of evolocumab 420 mg in the abdomen, thigh or upper arm. The study drug (evolocumab) prefilled injector pens are provided by Amgen
Other:
Placebo 1milliliter (mL) Subcutaneous Injection pre-filled injector Pen x 3 monthly for 6 months.
The study subjects randomized to the treatment study arm will receive monthly subcutaneous injections of Placebo in the abdomen, thigh or upper arm. The Placebo prefilled injector pens are provided by Amgen

Locations

Country Name City State
United States University of Southern California Los Angeles California

Sponsors (2)

Lead Sponsor Collaborator
Leonardo Clavijo Amgen

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Evolocumab effect in lower extremity arterial perfusion in ankle-brachial indices (ABI). To evaluate changes in lower extremity arterial perfusion in patients with PAD at baseline and after 6 month therapy with evolocumab, measured by systolic pressure rate changes in ankle-brachial indices (ABI).
The rest ABI will be calculated by the dorsalis pedis and posterior tibialis arteries highest systolic pressure value (in mmHg) of each foot divided by the brachial artery highest systolic pressure (in mmHg) of both arms.
six months
Other Evolocumab effect in lower extremity arterial perfusion pressure in post-exercise ankle-brachial indices. To evaluate changes in lower extremity arterial perfusion in patients with PAD at baseline and after 6 month therapy with evolocumab, measured by systolic pressure rate changes in post-exercise ankle-brachial indices (ABI).
The post-exercise ABI will be calculated by the dorsalis pedis and posterior tibialis arteries highest systolic pressure value (in mmHg) of each foot divided by the brachial artery highest systolic pressure (in mmHg) of both arms and assessed by using a standardized treadmill walking protocol at a 2% progressive grade every 2 minutes and 2 miles per hour until symptoms force the subject to stop.
six months
Other Evolocumab effect in lower extremity arterial perfusion pressure in Toe-Brachial pressure indices. To evaluate changes in lower extremity arterial perfusion in patients with PAD at baseline and after 6 month therapy with evolocumab, measured by systolic pressure rate changes toe-brachial indices (TBI).
The TBI will be determined by the great toe pressure value (in mmHg) of each foot divided by the brachial artery highest systolic pressure (in mmHg) of both arms.
six months
Other Evolocumab effect in lower extremity arterial perfusion in transcutaneous oxygen changes. To evaluate lower extremity arterial perfusion determined by changes in transcutaneous oxygen tension in the skin (in tcpo2 mmHg) at baseline and after 6 month therapy with evolocumab in patients with PAD.
Transcutaneous oxygen will be performed by placing electrodes on the skin at different levels of each leg, foot and chest for reference.
six months
Other Evolocumab effect in brachial endothelial function by changes in Flow Mediated Dilation (FMD). To evaluate changes in brachial endothelial function FMD determined by brachial artery diameter in response to shear stress of both arms in patients with PAD at baseline and after six months of therapy with Evolocumab compared with placebo.
The FMD will be measured as the percentage (%) change in brachial artery diameter from baseline in response to the increase flow achieved after the inflation of a pneumatic cuff to supra-systolic pressure for 5 minutes.
The ultrasound brachial images will be acquired using a LOGIQ eR7 ultrasound and a 12-L-RS linear array transducer and the images will be analyzed by the QUIPU automated cardiovascular suite, FMD studio software.
six months
Other Evolocumab effect in serum circulating biomarker oxidative LDL To evaluate changes on LDL oxidation by measuring oxidized LDL levels (oxLDL), performed using a sandwich ELISA method in patients with PAD at baseline and after six months of therapy with Evolocumab. six months
Other Evolocumab effect in serum circulating biomarker soluble CD36 (sCD36). To evaluate changes on human soluble CD36 levels at baseline and after 6 month therapy with evolocumab in patients with PAD by using a quantitative sandwich ELISA format. six months
Primary Evolocumab effect in pain free walking time (PFWT) in patients with PAD To evaluate change in pain free walking time (PFWT) in patients with PAD at baseline and after six months of therapy with Evolocumab.
PFWT will be measured in minutes, using a graded treadmill Gardner protocol with a constant speed of 2 miles per hour, increasing by 2% grade every 2 minutes.
six months
Secondary Evolocumab effect in maximal walking time (MWT) in patients with PAD To evaluate changes in maximal walking time (MWT) in patients with PAD at baseline and after six months of therapy with Evolocumab.
MWT will be measured in minutes, using a graded treadmill Gardner protocol with a constant speed of 2 miles per hour, increasing by 2% grade every 2 minutes.
six months
See also
  Status Clinical Trial Phase
Recruiting NCT06032065 - Sequential Multiple Assessment Randomized Trial of Exercise for PAD: SMART Exercise for PAD (SMART PAD) Phase 3
Active, not recruiting NCT03987061 - MOTIV Bioresorbable Scaffold in BTK Artery Disease N/A
Recruiting NCT03506633 - Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients N/A
Active, not recruiting NCT03506646 - Dietary Nitrate Supplementation and Thermoregulation N/A
Active, not recruiting NCT04677725 - NEtwork to Control ATherothrombosis (NEAT Registry)
Recruiting NCT05961943 - RESPONSE-2-PAD to Reduce Sedentary Time in Peripheral Arterial Disease Patients N/A
Recruiting NCT06047002 - Personalised Antiplatelet Therapy for Patients With Symptomatic Peripheral Arterial Disease
Completed NCT03185052 - Feasibility of Outpatient Care After Manual Compression in Patients Treated for Peripheral Arterial Disease by Endovascular Technique With 5F Sheath Femoral Approach N/A
Recruiting NCT05992896 - A Study of Loco-Regional Liposomal Bupivacaine Injection Phase 4
Completed NCT04635501 - AbsorbaSeal (ABS 5.6.7) Vascular Closure Device Trial N/A
Recruiting NCT04584632 - The Efemoral Vascular Scaffold System (EVSS) for the Treatment of Patients With Symptomatic Peripheral Vascular Disease From Stenosis or Occlusion of the Femoropopliteal Artery N/A
Withdrawn NCT03994185 - The Merit WRAPSODY™ Endovascular Stent Graft for Treatment of Iliac Artery Occlusive Disease N/A
Withdrawn NCT03538392 - Serranator® Alto Post Market Clinical Follow Up (PMCF) Study
Recruiting NCT02915796 - Autologous CD133(+) Cells as an Adjuvant to Below the Knee Percutaneous Transluminal Angioplasty Phase 1
Active, not recruiting NCT02900924 - Observational Study to Evaluate the BioMimics 3D Stent System: MIMICS-3D
Completed NCT02901847 - To Evaluate the Introduction of a Public Health Approach to Peripheral Arterial Disease (PAD) Using National Centre for Sport and Exercise Medicine Facilities. N/A
Not yet recruiting NCT02387450 - Reduced Cardiovascular Morbi-mortality by Sildenafil in Patients With Arterial Claudication Phase 2/Phase 3
Withdrawn NCT02126540 - Trial of Pantheris System, an Atherectomy Device That Provides Imaging While Removing Plaque in Lower Extremity Arteries N/A
Not yet recruiting NCT02455726 - Magnesium Oral Supplementation to Reduce Pain Inpatients With Severe Peripheral Arterial Occlusive Disease N/A
Completed NCT02022423 - Physical Activity Daily - An Internet-Based Walking Program for Patients With Peripheral Arterial Disease N/A